New Microgen drug will allow to treat cerebral palsy

| By | Clinical Trials, Microgen

NPO Microgen of Nacimbio holding company, a part of Rostec Corporation, has completed the studies on new indications for the use of Relatox, a drug for the treatment of spastic forms of cerebral palsy (CP) in patients aged 7-12 years old.

The results of studies confirm the efficacy and safety of the Russian type A botulinum toxin for the treatment of muscle spasticity of both upper and lower limbs. Earlier, the company has successfully completed Russia’s first similar clinical trials for the use of drug in children aged 13-17 years old, which allowed Relatox to become the first fully Russian-made medicine used in the treatment of that disease.

New indications will allow to use the drug for the treatment of a much larger number of children with cerebral palsy. These indications will be registered by the end of 2018, and Relatox will be allowed for the use in patients aged 7-12 years old as early as next year,” said Kirill Gaidash, General Director of NPO Microgen. “Currently, the drug is also being studied to extend its use for cerebral palsy in an even younger group of patients aged 2-6 years old.”

Relatox is the first and only type A botulinum toxin with full-cycle manufacturing in Russia. NPO Microgen has also completed clinical trials of Relatox for the use in patients with hyperhydrosis (excessive sweating).

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.